To illustrate the costs, Bio-Rad’s QC product–Liquichek Cardiac Markers Plus Control LT will be used. It has three levels and ten analytes: BNP, CK (Total), CK-MB, CRP (hs), Digitoxin, Homocysteine, Myoglobin, NT pro-BNP, Troponin I, and Troponin T. A typical crossover study is performed by obtaining one verified value for each level of the control for twenty days for a total of 20 data points per level or 60 data points in total.
The first example is a rudimentary cost analysis calculating total costs to run the crossover study with publicly available pricing on a cost-per-reportable basis and nationally published average labor rates. Actual costs will vary depending on contracted pricing with the lab and labor rates across the country. QC material costs are ignored for the purposes of this calculation due to the relative low cost compared to the reagents.
It is also assumed that each day of study, the technologist spends one hour preparing the materials, running the samples, verifying the information, documenting the results, and returning everything back to storage or waste. The supervisor is assumed to spend a total of two hours during the course of the study advising and reviewing data. A national average labor rate of $21/hour for a technologists and $32/hour for a supervisor, with a conservative markup for benefits of 35%, brings labor rates to $28 and $43, respectively.
|
Analytes
|
BNP
|
CK (Total)
|
CK-MB
|
CRP (hs)
|
Digitoxin
|
Homocysteine
|
Myoglobin
|
NT pro-BNP
|
Troponin I
|
Troponin T
|
Analyte Cost per Reportable
|
$15.00
|
$2.00
|
$2.00
|
$3.50
|
$2.00
|
$11.50
|
$3.25
|
$17.50
|
$4.25
|
$4.00
|
Total Analyte Costs (60 Samples)
|
$900.00
|
$120.00
|
$120.00
|
$210.00
|
$120.00
|
$690.00
|
$195.00
|
$1,050.00
|
$255.00
|
$240.00
|
Crossover Study Material Costs = $3,900.00
Labor Costs = $646.00
Total Costs = $4,546.00
In the above example, the calculations for all analytes are used. In reality, some of the analytes are competitive and would not be run on the same instruments, such as BNP and NT-pro-BNP. A second analysis of the same QC material looks at costs associated with a laboratory running only 6 of the 10 analytes and the cost is still significant. In the following scenario, a smaller lab’s higher pricing is taken into consideration.
|
Analytes
|
BNP
|
CK (Total)
|
CRP (hs)
|
Digitoxin
|
Myoglobin
|
Troponin T
|
Analyte Cost per Reportable
|
$25.00
|
$2.00
|
$3.50
|
$6.75
|
$3.50
|
$5.50
|
Total Analyte Costs (60 Samples)
|
$1,500.00
|
$120.00
|
$210.00
|
$405.00
|
$210.00
|
$330.00
|
Crossover Study Material Costs = $2,275.00
Labor Costs = $646.00
Total Costs = $2,921.00
When assessing whether it makes sense to change lots early, laboratories must acknowledge that a QC lot change needs to occur, and take into consideration the costs of the study. This would seem to indicate a cost deferment, not a cost savings. However, when assessed over a fixed period of time (5 or 10 years), the cost savings for a lab is quickly understood.
At the more conservative study savings of $2921, the laboratory only performs two crossover studies instead of three—over a five-year period.
$2921, while notable, is the cost for only one control product on one instrument using 6 reagents. The costs rise significantly for instruments with dozens of reagents, or labs with multiple instruments switching QC lots at the same time. Consider all the different QC products a laboratory uses, and entertain the idea of the lab not ensuring the full utilization of a QC lot to the end of its useful life. The lab is likely to be running multiple QC studies every year well before they are necessary. In this scenario, the cost per year for premature cross-over studies across multiple products could easily exceed $10,000 in reagent costs alone.
Conclusion
Cost-conscious laboratorians know that in this era of budget tightening, any potential savings that do not affect quality should be taken. Committing to the same lot of QC material can free up thousands of dollars that could be available for other resources.